SequelSEC

BIOLIFE SOLUTIONS INC BLFS

Electromedical & Electrotherapeutic Apparatus · CIK 0000834365 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$102.82M
Fiscal year ended 2026-06-30
Operating income
$2.98M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$845.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$17.49Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue8.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Electromedical & Electrotherapeutic Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue9.9%95th
Long-term debt / equity0.01x10th
Current ratio5.94x87th
SBC / revenue23.9%86th
FCF margin11.1%80th
R&D / revenue7.9%27th
Revenue YoY growth28.9%71th
Net margin-4.8%70th
Gross margin64.6%63th
Operating margin-17.3%57th

BIOLIFE SOLUTIONS INC (BLFS) reported revenue of $102.82M and net income of $57.98M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIOLIFE SOLUTIONS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

BIOLIFE SOLUTIONS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$102.82M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$2.98M
Net income$57.98M
Research & development$8.25M
Weighted-average diluted sharesUnavailable
Pretax income$8.07M
Income tax expense-$42.38M
Diluted EPSUnavailable
Selling, general & administrative$55.36M
General & administrative$45.53M
Selling & marketing$9.83M

Balance

BIOLIFE SOLUTIONS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$24.00M
Total assets$447.49M
Current assets$135.20M
Total liabilities$27.49M
Current liabilities$13.95M
Total equity incl. NCI$420.00M
Temporary (mezzanine) equityUnavailable
Inventory$35.59M
Accounts receivable$10.65M
Goodwill$208.59M
Long-term debt$0
Accounts payable$2.48M

Cash flow

BIOLIFE SOLUTIONS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$16.88M
Capital expendituresUnavailable
Investing cash flow-$8.24M
Financing cash flow-$16.54M
Net change in cashUnavailable
Stock-based compensation$21.64M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.68M

Derived

BIOLIFE SOLUTIONS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin2.9%
FCF marginUnavailable
SBC / revenue21.0%
Current ratio9.69x
Revenue YoY growth25.4%
Net margin56.4%
R&D / revenue8.0%
CapEx / revenueUnavailable
Long-term debt / equity0.00x
Effective tax rate-525.4%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BLFS in the interactive workspace to inspect any figure back to its filing.

Source filings

25-NSE · Filed 2026-10-06View SEC filing
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing

Companies in the same industry

ADMT AXGN CBLL CNMD CV ECOR ELMD ESMC FOCL GTHP HCIL HYPR

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.